Gregory A. Daniels, MD:I think it’s critical to consider multiple inputs into these cases. Again, most cutaneous squamous cell cancers are handled very well with the dermatologist, and/or a surgeon. Because they’re low risk, they’re going to be resected, and the chance of recurrence is less than 10%.
However, when you start to get into those patients where reconstruction is going to be considered, or the risk of recurrence can be expected to be higher than 10%, it really makes sense to get a multidisciplinary team involvement. You’re already thinking that there may be application of radiation in the adjuvant setting perhaps, or you want them to better plan out the surgery and have other surgeons involved in the discussion. I think these high-risk patients deserve at least a consultation, if not a tumor board type setting where they could be discussed.
Because these patients may require involvement of people such as a plastic surgeon, reconstruction experts, as well as radiation and medical oncology, it helps to have a team with experience in bringing together these kinds of care. Often this is done at a large academic referral center. However, there are community practices that are well set up for having a multidisciplinary team approach, and that should be encouraged.
The factors to determine resectability really depend on a patient where cure is going to be a reasonable goal for the intervention, whether it’s surgery or radiation. It also depends on whether the toxicities or morbidities of those modalities fit with that patient’s expectations and the willingness to undergo these things.
For example, sometimes lesions are involving the side of the face, as these are sun-related cancers. That may involve removal of parts of the ear or a reconstruction of the nose. For some patients that’s acceptable, but for other patients it’s not acceptable. So, there are many factors that go in to what is a resectable tumor.
The definition of locally advanced is anything that is in the dermas and spreading in the dermas, but hasn’t entered the lymph nodes or distant organs. Lymph node involvement for cutaneous squamous cell would be considered metastatic disease, unlike some other cancers. I consider locally advanced to be those tumors that are borderline resectable or where the treatment would not be expected to lead to a cure.
Transcript edited for clarity.
Case: A 79-Year-Old Male With Metastatic CSCC
April 2016
May 2018
mRNA-4157 Plus Pembrolizumab Continues to Improve RFS in High-Risk Melanoma
December 18th 2023Findings from 3-year follow-up of KEYNOTE-942/mRNA-4157-P201 show that the cancer vaccine mRNA-4157 plus pembrolizumab reduced the risk of recurrence or death in patients with stage III/IV melanoma following resection.
Read More
Managing Expectations of Treatment for Infiltrative Basal Cell Carcinoma
November 10th 2023In an event comoderated by Michael K. Wong, MD, PhD, FRCPC, and Anokhi Jambusaria, MD, MSCE, the 2 key opinions leaders discussed the hypothetical patient case of an 88-year-old man with a nonhealing ulcer on the lateral aspect of his nose who received a diagnosis of infiltrative basal cell carcinoma.
Read More